Replies to post #448888 on Anavex Life Sciences Corp (AVXL)

[WolfofMia]

Why are you sorry and so repetitive lol?

Can someone please pin/sticky his post about needing more trials for approval and less than 50% chance with current data, seen or unsee (somehow).

You seem to keep want to state the same point over and over and over again.

Lastly didnt you say not to trust what the company says? Should it be both ways? nice!

I believe based on the totality of data, safety and unmet need that the chance of approval in Rett and AD are non-zero, but can't reconcile the results of the EXCELLENCE and P2b/3 AD trials with having chances > 50% - sorry!

[bas2020]

That would be a FUD spin of the headline. However, a more accurate interpretation is the enlightened view of a broader platform (beyond 2-73) based on additional studies. This, in addition to the successful trial results of 2-73 that will likely lead to approvals this year for AD, as well as Rett, if the Rett Syndrome org carries any weight. The overall QoL evidence is far too strong to deny. And the EMA has already reviewed the data and recommended an MAA submission for full approval.

The evidence is quite strong against your continued FUD narratives.

[powerwalker]

Lawyer talk for your "Prudent" comment.

[williamssc]

So basically your another concerned short. Got it.

[bas2020]

Hey FUDster, are you so blind to notice that Excellence was a Ph 2/3 trial while Avatar was a Ph 3?

Notice also the placement of the EXCELLENCE trial on the Stage timeline as apposed to the AVATAR trial.